OTCMKTS:COCPCocrystal Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cocrystal Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.04 -0.04 (-1.92 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$2.02Now: $2.04▼$2.4250-Day Range$1.23MA: $1.73▼$2.3652-Week Range$0.39Now: $2.04▼$3.04Volume3.64 million shsAverage Volume4.80 million shsMarket Capitalization$106.37 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Cocrystal Pharma has a potential upside of 145.1% from its current price of $2.04.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesCocrystal Pharma has received 90 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCocrystal Pharma has received 45 “underperform” votes. (Add your “underperform” vote.)Community SentimentCocrystal Pharma has received 66.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cocrystal Pharma and other stocks. Vote “Outperform” if you believe COCP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe COCP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:COCP Previous Symbol CUSIPN/A CIKN/A Webwww.cocrystalpharma.com Phone+1-425-3987178Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees11 Outstanding Shares52,141,000Market Cap$106.37 million Next Earnings DateN/A OptionableNot Optionable $2.04 -0.04 (-1.92 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive COCP News and Ratings via Email Sign-up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Cocrystal Pharma (OTCMKTS:COCP) Frequently Asked Questions How has Cocrystal Pharma's stock been impacted by COVID-19 (Coronavirus)? Cocrystal Pharma's stock was trading at $1.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, COCP shares have increased by 61.9% and is now trading at $2.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cocrystal Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cocrystal Pharma. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma Inc (OTCMKTS:COCP) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.03. View Cocrystal Pharma's earnings history. What price target have analysts set for COCP? 2 Wall Street analysts have issued 12-month price objectives for Cocrystal Pharma's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Cocrystal Pharma's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 145.1% from the stock's current price. View analysts' price targets for Cocrystal Pharma. Has Cocrystal Pharma been receiving favorable news coverage? Headlines about COCP stock have trended very positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cocrystal Pharma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Cocrystal Pharma. Who are some of Cocrystal Pharma's key competitors? Some companies that are related to Cocrystal Pharma include Inventiva (IVA), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Tiziana Life Sciences (TILS), Synairgen (SNG), ProMetic Life Sciences (PLI), IMV (IMV), Fennec Pharmaceuticals (FRX), Rafael (RFL), Ergomed (ERGO), Pfenex (PFNX), Verona Pharma (VRP) and Medicenna Therapeutics (MDNA). View all competitors. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Opko Health (OPK), KKR & Co Inc (KKR), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OpGen (OPGN), VBI Vaccines (VBIV), Ibio (IBIO), Vaxart (VXRT) and Gilead Sciences (GILD). Who are Cocrystal Pharma's key executives? Cocrystal Pharma's management team includes the following people: Dr. Gary L. Wilcox, Co-Founder, Chairman & CEO (Age 73, Pay $201k)Dr. Sam Lee, Co-Founder & Pres (Age 60, Pay $241k)Mr. James J. Martin CPA, M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 53, Pay $231k)Dr. Roger D. Kornberg, Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist & Director (Age 73) What is Cocrystal Pharma's stock symbol? Cocrystal Pharma trades on the OTCMKTS under the ticker symbol "COCP." Who are Cocrystal Pharma's major shareholders? Cocrystal Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include UBS Group AG (0.03%). View institutional ownership trends for Cocrystal Pharma. Which institutional investors are buying Cocrystal Pharma stock? COCP stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Cocrystal Pharma. How do I buy shares of Cocrystal Pharma? Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cocrystal Pharma's stock price today? One share of COCP stock can currently be purchased for approximately $2.04. How big of a company is Cocrystal Pharma? Cocrystal Pharma has a market capitalization of $106.37 million. Cocrystal Pharma employs 11 workers across the globe. What is Cocrystal Pharma's official website? The official website for Cocrystal Pharma is www.cocrystalpharma.com. How can I contact Cocrystal Pharma? Cocrystal Pharma's mailing address is 1860 Montreal Rd, TUCKER, GA 30084-5709, United States. The company can be reached via phone at +1-425-3987178. This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
